Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam.
paper
Cited
Public
Unavailable
- Authors
- Addolorato, Giovanni; Leggio, Lorenzo; Abenavoli, Ludovico; Agabio, Roberta; Caputo, Fabio; Capristo, Esmeralda; Colombo, Giancarlo; Gessa, Gian Luigi; Gasbarrini, Giovanni
- Year
- 2006
- Journal
- The American journal of medicine
- PMID
- 16490478
- DOI
- 10.1016/j.amjmed.2005.08.042
PURPOSE: Benzodiazepines are the drugs of choice in the treatment of alcohol withdrawal syndrome (AWS). Recent data have shown that baclofen may reduce AWS symptoms. At present, no comparative studies between baclofen and any benzodiazepine used in AWS treatment are available. Accordingly, the present study was designed to compare efficacy, tolerability and safety of baclofen versus diazepam in the treatment of AWS. SUBJECTS AND METHODS: Thirty-seven patients with AWS were enrolled in the study and randomly divided into 2 groups. Baclofen (30 mg/day for 10 consecutive days) was orally administered to 18 patients (15 males, 3 females; median age: 46.5 years). Diazepam (0.5-0.75 mg/kg/day for 6 consecutive days, tapering the dose by 25% daily from day 7 to day 10) was orally administered to 19 patients (17 men, 2 women; median age: 42.0 years). The Clinical Institute Withdrawal Assessment (CIWA-Ar) was used to evaluate physical symptoms of AWS. RESULTS: Both baclofen and diazepam significantly decreased CIWA-Ar score, without significant differences between the 2 treatments. When CIWA-Ar subscales for sweating, tremors, anxiety and agitation were evaluated singly, treatment with baclofen and diazepam resulted in a significant decrease in sweating, tremors and anxiety score, without significant differences between the 2 drug treatments. Both treatments decreased the agitation score, although diazepam was slightly more rapid than baclofen. CONCLUSION: The efficacy of baclofen in treatment of uncomplicated AWS is comparable to that of the "gold standard" diazepam. These results suggest that baclofen may be considered as a new drug for treatment of uncomplicated AWS.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| The genetic epidemiology of substance use disorder: A review. | 2017 | 28938182 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy. | Guiraud J et al. | β | 2024 | β |
| Current evidence and clinical utility of phenobarbital for alcohol withdrawal syndrome. | Nishimura Y et al. | β | 2023 | β |
| Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients. | Trujillo P et al. | β | 2022 | β |
| Intact Error-Related Negativity at the Start of a Three-Week Detoxification Program Reflects a Short-Term Protective Factor Against Relapse in Alcoholic Patients: Some Preliminary Evidence from a Follow-up Event-Related Potentials Study. | Dousset C et al. | β | 2022 | β |
| Preventive Effects of Baclofen but Not Diazepam on Hippocampal Memory and Glucocorticoid Alterations After Prolonged Alcohol Withdrawal in Mice. | Nadia H et al. | β | 2022 | β |
| Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. | Garbutt JC et al. | β | 2021 | β |
| Non-medical use of benzodiazepines and GABA analogues in Europe. | Hockenhull J et al. | β | 2021 | β |
| The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. | Agabio R et al. | β | 2021 | β |
| Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). | Addolorato G et al. | β | 2020 | β |
| Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. | Addolorato G et al. | β | 2020 | β |
| Neurophysiological markers of cue reactivity and inhibition subtend a three-month period of complete alcohol abstinence. | Campanella S et al. | β | 2020 | β |
| Authors' reply to commentary on "Gulati P, Chavan BS, Sidana A. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome". | Gulati P et al. | β | 2019 | β |
| Baclofen for alcohol withdrawal. | Liu J et al. | β | 2019 | β |
| Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. | Gulati P et al. | β | 2019 | β |
| Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol. | Caputo F et al. | β | 2019 | β |
| Targeting the Glucocorticoid Receptors During Alcohol Withdrawal to Reduce Protracted Neurocognitive Disorders. | BΓ©racochΓ©a D et al. | β | 2019 | β |
| An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with vs. without chronic pretreatment with high-dosage baclofen. | Martinez L et al. | β | 2018 | β |
| Baclofen and the Alcohol Withdrawal Syndrome-A Short Review. | Cooney G et al. | β | 2018 | β |
| Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. | Mosoni C et al. | β | 2018 | β |
| Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. | Rose AK et al. | β | 2018 | β |
| Mephenesin: Is There a Progression in Cases of Substance Use Related Disorders in France? | Chevallier C et al. | β | 2018 | β |
| Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review. | Bharadwaj B et al. | β | 2018 | β |
| Suppressing Effect of Baclofen on Multiple Alcohol-Related Behaviors in Laboratory Animals. | Colombo G et al. | β | 2018 | β |
| The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. | de Beaurepaire R et al. | β | 2018 | β |
| Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning. | Boels D et al. | β | 2017 | β |
| Baclofen for alcohol withdrawal. | Liu J et al. | β | 2017 | β |
| Management of alcohol misuse in patients with liver diseases. | Peng JL et al. | β | 2017 | β |
| Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. | Gupta M et al. | β | 2017 | β |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | β | 2017 | β |
| The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. | Hauser P et al. | β | 2017 | β |
| Application of high-resolution mass spectrometry to determination of baclofen in a case of fatal intoxication. | Szpot P et al. | β | 2016 | β |
| A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. | Girish K et al. | β | 2016 | β |
| Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users? | Kleczkowska P et al. | β | 2016 | β |
| Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial. | Vourc'h M et al. | β | 2016 | β |
| Benzodiazepine dependence in subjects with alcohol use disorders: what prevalence? | Morel A et al. | β | 2016 | β |
| Clinical experience of baclofen in alcohol dependence: A chart review. | Rozatkar AR et al. | β | 2016 | β |
| How can we Improve on Modeling Nicotine Addiction to Develop Better Smoking Cessation Treatments? | Shoaib M et al. | β | 2016 | β |
| Pharmacotherapy of alcoholic liver disease in clinical practice. | Rosato V et al. | β | 2016 | β |
| Phenobarbital compared to benzodiazepines in alcohol withdrawal treatment: A register-based cohort study of subsequent benzodiazepine use, alcohol recidivism and mortality. | Askgaard G et al. | β | 2016 | β |
| Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. | Litten RZ et al. | β | 2016 | β |
| Radiation protective effects of baclofen predicted by a computational drug repurposing strategy. | Ren L et al. | β | 2016 | β |
| Role of GABA(B) receptors in learning and memory and neurological disorders. | Heaney CF et al. | β | 2016 | β |
| Treatment of alcohol use disorders in patients with alcoholic liver disease. | Addolorato G et al. | β | 2016 | β |
| Alcohol and violence: neuropeptidergic modulation of monoamine systems. | Miczek KA et al. | β | 2015 | β |
| Alcohol withdrawal delirium - diagnosis, course and treatment. | Mainerova B et al. | β | 2015 | β |
| Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. | Sachdeva A et al. | β | 2015 | β |
| A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. | Leggio L et al. | β | 2015 | β |
| Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain. | Keegan BM et al. | β | 2015 | β |
| Identification and management of alcohol withdrawal syndrome. | Mirijello A et al. | β | 2015 | β |
| Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns--a cohort study. | Dupouy J et al. | β | 2014 | β |
| Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. | Morley KC et al. | β | 2014 | β |
| Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. | Reddy VK et al. | β | 2014 | β |
| GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. | Agabio R et al. | β | 2014 | β |
| Pharmacological approaches to reducing craving in patients with alcohol use disorders. | Haass-Koffler CL et al. | β | 2014 | β |
| Pharmacotherapy of acute alcoholic hepatitis in clinical practice. | Abenavoli L et al. | β | 2014 | β |
| Preventive Effects of Forced Exercise against Alcohol-induced Physical Dependency and Reduction of Pain Perception Threshold. | Motaghinejad M et al. | β | 2014 | β |
| Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study. | Pommier P et al. | β | 2014 | β |
| Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial. | Caputo F et al. | β | 2014 | β |
| Efficacy and tolerability of baclofen in substance use disorders: a systematic review. | Agabio R et al. | β | 2013 | β |
| Increased Ethanol Consumption Following Chronic Psychosocial Stress: Do Oxytocin and Baclofen Hold any Therapeutic Promise? | Lee MR et al. | β | 2013 | β |
| The effectiveness of pharmacological approaches in the treatment of alcohol withdrawal syndrome (AWS): a literature review. | Cooper E et al. | β | 2013 | β |
| Alcohol withdrawal syndrome. | Carlson RW et al. | β | 2012 | β |
| Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. | Leggio L et al. | β | 2012 | β |
| Comparison of the effect of the GABAΞ receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. | Maccioni P et al. | β | 2012 | β |
| Discovering genes involved in alcohol dependence and other alcohol responses: role of animal models. | Buck KJ et al. | β | 2012 | β |
| Dystonia as a presenting feature of alcohol withdrawal. | Bijjal S et al. | β | 2012 | β |
| EASL clinical practical guidelines: management of alcoholic liver disease. | European Association for the Study of Liver | β | 2012 | β |
| Effects of alcohol on the membrane excitability and synaptic transmission of medium spiny neurons in the nucleus accumbens. | Marty VN et al. | β | 2012 | β |
| Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. | Gorsane MA et al. | β | 2012 | β |
| Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. | Addolorato G et al. | β | 2012 | β |
| Pharmacotherapy for adolescent alcohol use disorder. | Clark DB | β | 2012 | β |
| Substitution therapy for alcoholism: time for a reappraisal? | Chick J et al. | β | 2012 | β |
| [Baclofen for alcohol addiction]. | Helland A et al. | β | 2011 | β |
| Baclofen for alcohol withdrawal. | Liu J et al. | β | 2011 | β |
| An approach to the patient with substance use and abuse. | Maldonado JR | β | 2010 | β |
| [A system of prescriptions without drug approval: example of baclofen]. | Rolland B et al. | β | 2010 | β |
| Benzodiazepines for alcohol withdrawal. | Amato L et al. | β | 2010 | β |
| Chemistry and pharmacology of GABAB receptor ligands. | Froestl W | β | 2010 | β |
| Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. | Garbutt JC et al. | β | 2010 | β |
| GABA(A) receptors in the dorsal raphΓ© nucleus of mice: escalation of aggression after alcohol consumption. | Takahashi A et al. | β | 2010 | β |
| GABAB receptors in addiction and its treatment. | Tyacke RJ et al. | β | 2010 | β |
| GABAB receptors in reward processes. | Vlachou S et al. | β | 2010 | β |
| Medication treatment of different types of alcoholism. | Johnson BA | β | 2010 | β |
| Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. | Di Nicola M et al. | β | 2010 | β |
| Acute interaction of baclofen in combination with alcohol in heavy social drinkers. | Evans SM et al. | β | 2009 | β |
| A selective ALDH-2 inhibitor reduces anxiety in rats. | Overstreet DH et al. | β | 2009 | β |
| Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. | Fattore L et al. | β | 2009 | β |
| Mapping a barbiturate withdrawal locus to a 0.44 Mb interval and analysis of a novel null mutant identify a role for Kcnj9 (GIRK3) in withdrawal from pentobarbital, zolpidem, and ethanol. | Kozell LB et al. | β | 2009 | β |
| Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. | Maccioni P et al. | β | 2009 | β |
| Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. | Addolorato G et al. | β | 2009 | β |
| Acute alcohol intoxication. | Vonghia L et al. | β | 2008 | β |
| Baclofen in the management of inhalant withdrawal: a case series. | Muralidharan K et al. | β | 2008 | β |
| Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients. | Leggio L et al. | β | 2008 | β |
| New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. | Leggio L et al. | β | 2008 | β |
| Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. | Leggio L et al. | β | 2008 | β |
| Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. | Knapp DJ et al. | β | 2007 | β |
| Baclofen for alcohol withdrawal: not comparable to the gold standard (benzodiazepines). | Saitz R | β | 2007 | β |
| Baclofen not comparable to diazepam for alcohol withdrawal. | O'Connor AB et al. | β | 2007 | β |
| Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. | Agabio R et al. | β | 2007 | β |
| Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety. | Jacobson LH et al. | β | 2007 | β |
| CGP7930: a positive allosteric modulator of the GABAB receptor. | Adams CL et al. | β | 2007 | β |
| Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. | Addolorato G et al. | β | 2007 | β |
| Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. | Nava F et al. | β | 2007 | β |
| Growth hormone response to the GABA-B agonist baclofen in 3-week abstinent alcoholics. | Ozsoy S et al. | β | 2007 | β |
| Prolonged, severe intrathecal baclofen withdrawal syndrome: a case report. | Hansen CR et al. | β | 2007 | β |
| Reducing effect of the positive allosteric modulator of the GABA(B) receptor, GS39,783, on alcohol self-administration in alcohol-preferring rats. | Maccioni P et al. | β | 2007 | β |
| Substance-related disorders in adults. | Leikin JB | β | 2007 | β |
| Baclofen: a new drug for the treatment of alcohol dependence. | Addolorato G et al. | β | 2006 | β |